February 27-28, 2020. Washington DC. Inotrem will attend the 3CT Workshop (Critical Care Clinical Trialists) that will take place at the French Embassy on February 27th and 28th 2020 in Washington DC. During the 2-days Symposium, Inotrem will present the design of its ASTONISH Phase IIb clinical trial for Nangibotide
January 13-16, 2020. San Francisco. Inotrem will participate to the annual J.P. Morgan Healthcare Conference. It is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
December 3, 2019. Nancy. Cecile Jouclas, Inotrem’s Administrative and Financial Officer, will participate to the Deeptech Tour organized by the BPI. Cecile will be a host at the workshop “What tools to finance your deeptech project?” that will take place on the Université de Lorraine’s campus. Throughout France, the Deeptech
Paris (France). November 21. 2019. Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient
October 8-12 in Chania, Crete, Greece. Marc Derive, Co-founder and CSO of Inotrem, will present new preclinical data during the 18th ESS congress and 9th Congress of the IFSS, entitled “TREM-1 pharmacological inhibition by LR12/nangibotide improves survival and controls vascular leakage during experimental endotoxic shock in mice” in a session
28 September – 2 October 2019 in Berlin, Germany. European Society of Intensive Care Medicine’s (ESICM) annual congress attracts audiences of over 6,000 physicians, anesthetists, trainees and nursing and allied health professionals, every year, from every continent and 97 different countries. A diverse faculty of more than 300 international speakers
Paris, September 12th. 2019. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes,announced today a €39 million Series B financing led by Morningside Ventures, joined byInvus with participation from existing investors Andera Partners, Sofinnova Partners
Paris, September 3rd. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nangibotide development program for the treatment of septic shock. Nangibotide, which Phase IIb has just been
Paris (France). August 6. 2019. Inotrem S.A., a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for the ASTONISH trial (Phase IIb) where the safety, tolerance and efficacy of nangibotide (LR12),
July 9. 2019 in Paris. Jean-Jacques Garaud, CEO at Inotrem, will be a speaker at the Solebury Trout Summer Investor tour, hosted by Andera Partners in Paris.
June 24. & June 25. 2019 in Paris. Inotrem will attend this exclusive event organized by France Biotech which brings together French and European HealthTech leaders, large pharmaceutical companies and international investors in health innovation.
June 17. 2019 in Paris (La Défense). Dr. Margarita Salcedo Magguilli, CDP at Inotrem, will be speaking at the roundtable “New regulatory paths to innovation” during the 3rd Biotech Meeting Day (Les Rencontres de la Biotech) organized by Pharmaceutiques.
May 5. 2019. Discover the interview of Jean-Jacques Garaud, CEO of Inotrem, laying out Inotrem’s recent milestones and internationalization strategy in PharmaBoardRoom.
February 19. 2019 in Paris. Martin Koch, COO of Inotrem, participates to “Market Access and Biotechnologies”, a panel discussion organized by France Biotech, France’s main non-profit organization which brings together the country’s leading innovative health companies and their expert partners. www.france-biotech.fr
January 23.-26. 2019 in Paris. Reanimation 2019 is the Annual congress organized by the French Intensive Care Society (www.srlf.org). Dr. Bruno François, Coordinating Physician at the CHU of Limoges, will present the MOT-C-201 Clinical Trial Results regarding safety and tolerability of nangibotide (LR12) in patients with septic shock. www.reanimation-lecongres.com
The study demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock Paris, October 1st. 2018. Inotrem S.A., a biotechnology focused on the modulation of the TREM pathway for the management of inflammatory syndromes, announced positive results for its Phase IIa study that demonstrated the
October 1-3, 2018 in Bangkok, Thailand The International Sepsis Forum (ISF) is an international collaboration to reduce the global burden of sepsis guided by prominent academics from around the world. Sepsis 2018 will be held as a joint meeting with the Thai Society of Critical Sepsis 2018 Medicine. http://internationalsepsisforum.com/
October 3-4. 2018 in Basel, Switzerland The 18th Annual Biotech in Europe Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading
October 23. 2018 in Tokyo, Japan Sofinnova Partners is an independent venture capital firm based in Paris. Over the past 40 years, the firm has financed and accompanied almost 500 companies. http://www.sofinnova.fr/en/
November 5-7. 2018 in Copenhagen, Denmark The 23rd annual international partnering conference BIO-Europe offers world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business. https://ebdgroup.knect365.com/bioeurope/
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices